Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

4 May 2021

Lobe Sciences Acquires Vitamind Line of Wellness Products

By Microdose

Press Releases

4 May 2021

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

3 May 2021

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

By Microdose

Press Releases

29 Apr 2021

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS…

Events subsequent to quarter end include $40....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

29 Apr 2021

Lobe Sciences Announces Filing of PCT Application

By Microdose

Press Releases

29 Apr 2021

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

28 Apr 2021

Awakn Life Sciences Initiates New Chemical Entity Development Program With Evotec As Research Partner And Addiction Expert, Prof. David Nutt, As Program Lead

Defining clear development pathway for next generation of psychedelic medicines to treat addiction Awakn announces today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline...

By Microdose

Press Releases

28 Apr 2021

Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

28 Apr 2021

Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services

Toronto, Ontario–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.